GCLC and breast cancer: The Pharmacological prohibition of NQO1 and GCLC is a new therapeutic strategy for overcoming tamoxifen-resistance and also shows that the prediction of NQO1 as a biomarker has the significant prognostic value of tumor recurrence in BC patients [64].